The rounds this investor is named on, who it invests beside, and where it shows up.
Named on one round in the feed.
Corporationharbourbiomed.comSince 2026-05-04
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |